Cutler Group’s Madrigal Pharmaceuticals MDGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $4.22M | Buy |
15,800
+2,300
| +17% | +$542K | 1.37% | 6 |
|
|
2023
Q4 | $3.12M | Buy |
13,500
+3,200
| +31% | +$560K | 0.28% | 71 |
|
|
2023
Q3 | $1.5M | Buy |
10,300
+3,400
| +49% | +$640K | 0.15% | 155 |
|
|
2023
Q2 | $1.59M | Buy |
6,900
+2,800
| +68% | +$758K | 0.22% | 97 |
|
|
2023
Q1 | $993K | Buy |
+4,100
| New | +$1.12M | 0.1% | 204 |
|
|
2022
Q4 | – | Sell |
-50
| Closed | -$4.89K | – | 4891 |
|
|
2022
Q3 | $3K | Sell |
50
-2,465
| -98% | -$171K | ﹤0.01% | 3986 |
|
|
2022
Q2 | $180K | Sell |
2,515
-562
| -18% | -$41.3K | 0.01% | 1077 |
|
|
2022
Q1 | $301K | Buy |
3,077
+1,507
| +96% | +$127K | 0.02% | 939 |
|
|
2021
Q4 | $133K | Sell |
1,570
-230
| -13% | -$18.9K | 0.01% | 1633 |
|
|
2021
Q3 | $143K | Buy |
1,800
+260
| +17% | +$22.5K | 0.01% | 1612 |
|
|
2021
Q2 | $150K | Buy |
1,540
+640
| +71% | +$75.8K | 0.01% | 1547 |
|
|
2021
Q1 | $105K | Buy |
900
+700
| +350% | +$81.6K | 0.01% | 1738 |
|
|
2020
Q4 | $22K | Sell |
200
-3,000
| -94% | -$367K | ﹤0.01% | 2623 |
|
|
2020
Q3 | $379K | Buy |
3,200
+2,018
| +171% | +$219K | 0.02% | 624 |
|
|
2020
Q2 | $133K | Sell |
1,182
-318
| -21% | -$31.3K | 0.01% | 1119 |
|
|
2020
Q1 | $100K | Buy |
1,500
+95
| +7% | +$7.92K | 0.01% | 1331 |
|
|
2019
Q4 | $128K | Sell |
1,405
-300
| -18% | -$29.1K | 0.01% | 1066 |
|
|
2019
Q3 | $147K | Buy |
1,705
+1,162
| +214% | +$109K | 0.01% | 852 |
|
|
2019
Q2 | $56K | Sell |
543
-2,955
| -84% | -$317K | 0.01% | 1470 |
|
|
2019
Q1 | $438K | Buy |
+3,498
| New | +$435K | 0.05% | 359 |
|
|
2018
Q4 | – | Sell |
-2,666
| Closed | -$413K | – | 4330 |
|
|
2018
Q3 | $570K | Buy |
2,666
+1,666
| +167% | +$418K | 0.04% | 424 |
|
|
2018
Q2 | $279K | Buy |
+1,000
| New | +$176K | 0.02% | 646 |
|
|
2017
Q2 | – | Sell |
-547
| Closed | -$8K | – | 6764 |
|
|
2017
Q1 | $8K | Hold |
547
| – | – | ﹤0.01% | 4280 |
|
|
2016
Q4 | $8K | Hold |
547
| – | – | ﹤0.01% | 4440 |
|
|
2016
Q3 | $6K | Sell |
547
-1
| -0.2% | -$10 | ﹤0.01% | 4772 |
|
|
2016
Q2 | $4K | Hold |
548
| – | – | ﹤0.01% | 5157 |
|
|
2016
Q1 | $4K | Buy |
548
+47
| +9% | +$393 | ﹤0.01% | 5053 |
|
|
2015
Q4 | $6K | Buy |
+501
| New | +$13.7K | ﹤0.01% | 4714 |
|
Other funds holding MDGL
BBA
ACA
PC
PA
Cutler Group's MDGL Position: Q1 2024 in Review
Cutler Group increased its Madrigal Pharmaceuticals (MDGL) stake by 17% in Q1 2024, buying an estimated $542K and bringing the position to 15,800 shares worth $4.22M. The position accounts for 1.37% of the portfolio, ranked #6.
Cutler Group first reported a position in MDGL in Q4 2015 and has held it in 28 quarters since. 268 funds tracked by Wall St. Rank hold MDGL as of Q1 2024.
- Cutler Group held 15,800 shares of Madrigal Pharmaceuticals worth $4.22M as of Q1 2024.
- Cutler Group bought 2,300 Madrigal Pharmaceuticals shares in Q1 2024, an estimated $542K.
- Madrigal Pharmaceuticals made up 1.37% of Cutler Group's portfolio in Q1 2024, its #6 holding.
- Cutler Group first reported a position in Madrigal Pharmaceuticals in Q4 2015 and has held it in 28 quarters since.
- 268 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2024.
Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.